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a  b  s  t  r  a  c  t
The  renin–angiotensin  (Ang)  system  (RAS)  plays  an  important  role  in  the  control  of glucose  metabolism
and  glycemia.  Several  studies  demonstrated  that the  effects  of angiotensin-(1-7)  are  mainly  opposite  to
the  actions  of  biological  angiotensin  II. Recent  studies  have demonstrated  that  rats  with  increased  cir-
culating  angiotensin-(1-7),  acting  through  the  G protein  coupled  receptor  Mas,  have  enhanced  glucose
tolerance  and  insulin  sensitivity,  presenting  improved  metabolic  parameters.  However,  there  is  no  data
regarding  the  role  of  angiotensin-(1-7)–Mas  axis  in  hepatic  glycemic  metabolism.  In  the  present  study,
the  gluconeogenesis  and  glycogenolysis  was  investigated  in  Sprague–Dawley  (SD)  and in TGR(A1-7)3292
(TGR)  rats  which  present  approximately  twofold  increase  in  plasma  Ang-(1-7)  levels  compared  to  SD. The
pyruvate administration  in  fasted  rats  showed  a decreased  synthesis  of  glucose  in  TGR  compared  to  the  SD
rats, pointing  to a downregulation  of  gluconeogenesis.  Supporting  this  data,  the mRNA  evaluation  of  glu-
coneogenic  enzymes  showed  a signiﬁcant  reduction  in  phosphoenolpyruvate  carboxykinase  reinforced
by  a signiﬁcantly  diminished  expression  of  hepatocyte  nuclear  factor  4  (HNF-4),  responsible  for  the
regulation  of  gluconeogenic  enzymes.  In conclusion  our data  show  that  the  improved  glucose  metabolism
induced  by Ang-(1-7)  could  be  due, at least  in  part, to a downregulation  of  hepatic  gluconeogenesis.. Introduction
Glucose is the main energy source of the body and circulating
lucose is derived from three sources: intestinal absorption during
he fed state, in addition to glycogenolysis and gluconeogenesis
uring fasted states [1]. Gluconeogenesis takes place mainly in the
iver, from precursors such as alanine and glutamine through pyru-
ate and ﬁnally glucose [6]. The HNF-4 gene, a hepatocyte nuclear
actor, regulates the expression of genes responsible for gluco-
eogenic enzymes. Thus it plays an important role in this pathway
nd is considered a marker of gluconeogenesis [27].
The renin–angiotensin system (RAS) is now recognized to have
 considerable inﬂuence in the development of cardiovascular and
etabolic disorders. The RAS is composed of an enzymatic cas-
ade in which angiotensinogen (AGT) is converted to Angiotensin
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(Ang) I by renin and subsequently to Ang II by angiotensin-
converting-enzyme (ACE). Another important component of RAS,
the Ang-(1-7), is primarily formed from Ang II by angiotensin con-
verting enzyme 2 (ACE2). It is well documented that Ang II, acting
via its AT1 receptor, is a potent proinﬂammatory, pro-oxidant, and
prothrombotic agent that interferes with several steps of intra-
cellular insulin signaling. The ACE2/Ang-(1-7)/Mas axis has been
suggested as an important counterregulatory arm in the RAS with
opposite effects to those of ACE/Ang II/AT1. The Ang-(1-7) can
produce NO-dependent vasodilation as well as antiarrhythmic,
antiproliferative, and antithrombotic effects [5,16,21–23].
Recently it was  demonstrated that Mas-deﬁciency in FVB/N
mice induces dyslipidemia, lower glucose tolerance and insulin
sensitivity, hyperinsulinemia, hyperleptinemia, decreased glu-
cose uptake in white adipose cells, in addition to an increase
in adipose tissue mass. On the other hand, transgenic rats
with increased circulating Ang-(1-7) (TGR) have improved lipid
Open access under the Elsevier OA license.and glucose metabolism [22,23].  A recent study conﬁrmed the
increased Ang-(1-7) plasma levels in TGR (51.82 ± 6.3 in TGR vs.
29.17 ± 8.7 pg/mL in Sprague–Dawley rats); and also showed a
lower body weight (278.3 ± 13.3 g in TGR vs. 375.7 ± 10.2 g in
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prague–Dawley rats), improved insulin sensitivity and dimin-
shed triglycerides plasma levels (14.82 ± 3.77 mg/dL in TGR vs.
5.22 ± 3.39 mg/dL in Sprague–Dawley rats) in this model [23]
owever, the role of Ang-(1-7) in hepatic gluconeogenesis and
lycogenolysis pathways is still poorly understood. Thus, the
resent study evaluated both pathways in the liver of transgenic
ats which express Ang-(1-7) releasing fusion protein (TGR) show-
ng approximately twofold increase in Ang-(1-7) plasma levels
ompared to Sprague–Dawley (SD) rats.
. Materials and methods
.1. Animals
Ten TGR and control Sprague–Dawley (SD) rats were obtained
rom the transgenic animal facilities at Laboratory of Hypertension
Federal University of Minas Gerais, Belo Horizonte, Brazil). The ani-
als were kept under controlled light and temperature conditions,
ith free access to water and chow diet, in accordance to the ethical
uidelines of our institution.
.2. Tissue collection and blood measurements
Rats were sacriﬁced by decapitation and samples of blood and
epatic tissue were collected, weighed and immediately frozen
n dry ice and stored at −80 ◦C for further analysis. Serum was
btained after centrifugation (3200 rpm for 10 min  at 4 ◦C). ELISA
its were used to measure serum glucagon (ALPCO; Boston, USA)
10].
.3. Hepatic glycogen content
Hepatic glycogen was extracted and determined as glucose fol-
owing acid hydrolysis. Brieﬂy, liver samples were placed in tubes
ith 30% KOH (Sigma; St. Louis, MO,  USA) saturated with Na2SO4
Sigma; St. Louis, MO,  USA). The tubes were placed in a boiling water
ath for 1 h until a homogeneous solution was obtained. Absolute
thanol was added to precipitate the glycogen from the alkaline
igest. After centrifugation the supernatant was carefully aspirated
nd the glycogen washed. Glycogen precipitates were dissolved in
0 ml  distilled water. The contents of the ﬂasks were further diluted
ith water in a second volumetric ﬂask so as to yield a solution of
lycogen concentration of 3–30 mg/ml. Anthrone (Santa Cruz, CA,
SA) was carefully added to 2 ml  aliquots and the tubes were placed
n boiling water. After the tubes cooled down, the absorbance of the
amples was measured at 620 nm on a spectrophotometer. Glucose
t different concentrations was used for a calibration curve [23].
.4. Reverse transcription and real-time PCR
Total RNA from hepatic tissue was prepared using Tri-
ol reagent (Invitrogen Corp., San Diego, CA, USA), treated
ith DNAse and reverse transcribed with M-MLV (Invitrogen
orp.) using random hexamer primers. Levels of glucose-6-
hosphatase (G6Pase), phosphoenolpyruvate carboxykinase
PEPCK) and HNF4  mRNA were determined by real-time quan-
itative PCR using SYBR Green reagent (Applied Biosystems,
A, USA) in an ABI Prism 7000 platform (Applied Biosystems).
he following primer pairs were used: glucose-6-phosphatase
G6Pase) forward 5 -aacgtctgtctgtcccggatctac-3 ; G6Pase reverse
 -acctctggaggctggcattg-3 ; PEPCK forward 5 -tgcccatgcaaggcatca-
 ; PEPCK reverse 5 -tctcatggcagctcctacaaacac-3 ; hepatocyte
uclear factor 4 alpha (HNF4)  forward 5 -tgagcacctgctgcttgga-
 ; HNF4 reverse 5 -tcgaggatgcgaatggacac-3 ; -actin
orward 5 -tgacaggatgcagaaggaga-3 ; -actin reverse 5 -
agagccaccaatccacaca-3 [23,27].37 (2012) 247–251
2.5. Western blotting analysis
Proteins were extracted from hepatic tissue samples (∼300 mg)
of TGR and SD rats and 30 g of protein were resolved on SDS-PAGE
gels (10%) and then transferred onto nitrocellulose membranes.
Glycogen phosphorylase enzyme, PYGB/L/M (Santa Cruz Biotech-
nology; CA, USA), and -actin (internal control) (Cell Signaling
Beverly; MA,  USA) were probed with a polyclonal rabbit anti-
body (1:1000). Goat anti-rabbit IgG conjugated with peroxidase
(1:5000) was  used as a secondary antibody. The blots were visual-
ized using a chemiluminescence western blotting detection reagent
ECL; (Amersham Pharmacia Biotech, EUA) and revealed on a pho-
tographic ﬁlm (Kodak; USA) followed by quantiﬁcation using TINA
2.08c program (Raytest, Germany)
2.6. Glucagon and pyruvate challenge tests
For the serum glucagon measurement, glucagon extracted of
porcine pancreas (0.2 mg/g of body weight) was intraperitoneally
injected into overnight fasted rats. Glucose levels from tail blood
samples were monitored at 0, 10, 20, 30, 60, 120, 150 and 180 min
after injection using an Accu-Check glucometer (Roche Diagnostics
Corp.; Indianapolis, IN, USA).
For pyruvate challenge test, fasted overnight rats were injected
intraperitoneally with pyruvate (1 mg/g) as described by Sabio et al.
[18]. Glucose levels from tail blood samples were monitored at 0, 10,
20, 30, 45, 60, 90 and 120 min  after injection using an Accu-Check
glucometer (Roche Diagnostics Corp.; Indianapolis, IN, USA) [11].
2.7. Statistical analysis
Data are expressed as the mean ± SEM. The statistical signiﬁ-
cance of difference in mean values between TGR and SD rats was
assessed by unpaired Student’s t-test or two-way ANOVA (glucagon
and pyruvate challenge tests). Signiﬁcance level was set at p < 0.05.
3. Results
Twelve weeks old TGR rats (0.0269 ± 0.00067 g/g BW)  showed
no difference in liver weight corrected by body weight when com-
pared with SD rats. (0.0265 ± 0.00047 g/g BW)  as illustrated in
Fig. 1. Glucagon stimulation test also not demonstrate statistical
difference between fasted TGR rats and SD rats (Fig. 2). Analysis of
basal hepatic glycogen measurement showed no variation between
TGR (0.4005 ± 0.1562 mg/g) and SD rats (0.5825 ± 0.1778 mg/g) as
demonstrated in Fig. 2. In order to evaluate the gluconeogene-
sis pathway we performed the pyruvate challenge test (Fig. 1).
Pyruvate administration in fasting TGR showed a decrease in the
synthesis of glucose in these rats compared to the SD with the min-
imum peak for glycemic values of the curve in TGR rats at 30 min
(106.8 in SD vs. 85.73 in TGR; P < 0.01) and 45 min  (117.0 in SD vs.
98.00 in TGR; P < 0.01).
To understand the molecular mechanisms underlying changes
in gluconeogenesis and glycogenolysis we analyzed the levels
of glycongen phosphorylase enzyme, PYGB/L/M by Western
blotting method (Fig. 2). The total of PYG enzyme level was  not
altered (4.148 ± 0.6282 in TGR vs. 5.893 ± 0.4164 in SD rats). In
addition, real-time PCR analysis revealed a marked decrease in
PEPCK expression in TGR hepatic tissue (1.403 ± 0.1441 in SD vs.
0.4598 ± 0.2391 in TGR), without difference in G6Pase expression
in TGR and SD rats (0.7363 ± 0.09964 in SD vs. 1.133 ± 0.2475 in
TGR) as showed in Fig. 1. In order to conﬁrm the downregulation
in gluconeogenesis we  evaluated the mRNA expression of HNF-
4, responsible for the regulation of transcription enzymes on
gluconeogenesis pathway (Fig. 1), and we observed an important
V. Bilman et al. / Peptides 37 (2012) 247–251 249
Fig. 1. (A) Liver weight corrected by body weight (g) of 12 weeks-old TGR (n = 6) and SD (n = 6) male rats. (B) Expression of PEPCK. (C) Expression of G6Pase. (D) Pyruvate
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ecrease in TGR rats (0.7214 ± 0.1196 in TGR vs. 1.307 ± 0.2023 in
D).
. Discussion
It  is well documented that Ang-(1-7) presents several effects
pposite to those produced by Ang II [13,15,20,22,23], however,
his is the ﬁrst study evaluating the role of Ang-(1-7) on liver gluco-
eogenesis and glycogenolysis. The main result of the present study
as to show that transgenic rats with increased circulating Ang-(1-
) presents a decreased activation of the gluconeogenesis pathway,
emonstrated by the pyruvate challenge test accompanied by a
igniﬁcantly reduction in PEPCK and HNF4.
The role of Ang II in glucose metabolism is well established.
oimbra et al. [4] demonstrated that administration of Ang II
ncreases hepatic glucose output, mostly by activation of gluconeo-
enesis pathway in comparison to the glycogenolysis pathway. The
resent results point to a counterregulatory action of Angiotensin-
1-7) on gluconeogenesis, which opposes the effect of Ang II.
Gluconeogenesis process is controlled directly or indirectly by
any hormones, including insulin and glucagon [7].  The glucagon
timulation test was performed in fasted rats and no signiﬁcant
ifference was observed between fasted TGR and SD rats. How-
ver, this result can be attributed to the action of glucagon in all
he metabolic sensitive tissues of the rat (such as muscle) and not
xclusively in the liver.Glycogenolysis was evaluated through baseline hepatic glyco-
en concentration and levels of hepatic glycogen phosphorylase, an
llosteric enzyme responsible for catalyzing the phosphorylation
f glycogen to glucose1-P, playing a fundamental role in glycogen1 mg/g body weight). Blood samples were collected from the tail at indicated times
means ± SE. *P < 0.05.
metabolism [7,26].  There was no signiﬁcant difference in hepatic
glycogen phosphorylase levels analyzed by Western blotting. The
absence of alteration in glycogenolysis pathway can explain the
unaltered hepatic glycogen levels in TGR.
To evaluate gluconeogenesis pathway separately we  performed
the pyruvate challenge test [18]. The ﬁrst regulated step in
the gluconeogenic pathway from pyruvate and its precursors is
the pyruvate to oxaloacetate carboxylation, catalyzed by ATP-
dependent pyruvate carboxylase [8–10]. The pyruvate challenge
experiment showed that overnight fasted TGR rats have a decrease
in the glucose synthesis when compared to overnight fasted SD
rats, suggesting a downregulation in the gluconeogenesis pathway,
since overnight fasted rats have negligible amounts of preformed
glycogen.
In order to conﬁrm the downregulation of the gluconeogenesis
pathway, it was  evaluated the mRNA expression of the key enzymes
of this route. The expression of G6Pase, a multicomponent enzyme
system that hydrolyses glucose-6-phospate (G6P) to glucose in the
ﬁnal step of gluconeogenesis, showed no statistically difference in
TGR and SD rats. PEPCK, one of the main rate-limiting enzymes
of gluconeogenesis, simultaneously decarboxilates and phospho-
rylates oxaloacetate to phosphoenolpyruvate, had its expression
signiﬁcantly reduced in TGR when compared to SD rats. These
results suggest that the gluconeogenesis downregulation could be
due to the decreased expression of PEPCK.
Recently, it has been documented that HNF4  has been impli-
cated in gluconeogenesis through transcriptional regulation of
G6Pase and PEPCK, which are rate-limiting enzymes in this
process as discussed previously [27]. The mRNA expression of
HNF4 analysis by RT-PCR showed signiﬁcantly decreased levels
250 V. Bilman et al. / Peptides 37 (2012) 247–251
Fig. 2. (A) Glucagon stimulation test. Overnight-fasted rats were given an intraperitoneal injection of glucagon (0.2 mg/g body weight). (B) Glucagon serum levels. (C) Levels
of  basal hepatic glycogen. (D) Glycogen phosphorylase Western blotting analyses of hepatic tissue in TGR rats (n = 4) and Sprague–Dawley (SD) (n = 5) rats. (E) Illustrative
picture  of G6Pase Western blotting gel from TGR and SD rats. After incubation with primary and secondary antibody for glycogen phosphorylase detection, the membrane
was  stripped and incubated with primary and secondary antibody used to detect -actin. Data are presented as means ± SE. No statistically signiﬁcant differences between
the  groups were observed.
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[n TGR, when compared to SD rats. This ﬁnding pointed out to
 relation between Ang-(1-7) and HNF4, leading to an overall
ownregulation of gluconeogenesis. This result can be responsi-
le, at least in part, for the improved circulating glycemic proﬁle in
GR described previously [23].
In summary, the results obtained in the present study show that
ransgenic rats with increased Ang-(1-7) plasma levels, present
 lower activation of the gluconeogenesis pathway responsible
or glucose synthesis, without evidence of alteration in the hep-
tic glycogenolysis. This result is evidenced by the lower peaks
f plasma glucose levels in fasted TGR rats during pyruvate chal-
enge test. The primary mechanisms involved in this effect appear
o include a decrease in hepatocyte nuclear factor 4 (HNF-4)
xpression, probably leading to a down regulation of PEPCK, one
f the main rate-limiting enzymes of gluconeogenesis. These ﬁnd-
ngs suggest an important role of Ang-(1-7) in hepatic glucose
etabolism.
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